57 results
Page 2 of 3
6-K
EX-99.1
ya7x12 x0cp
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
424B7
tu2sip oaj7sso
5 May 22
Prospectus with selling stockholder info
12:00am
6-K
EX-99.1
wom8 o7w7negfkpa
14 Apr 22
Current report (foreign)
4:11pm
F-3ASR
gjbg37n
4 Apr 22
Automatic shelf registration (foreign)
4:08pm
6-K
EX-99.1
imyh650f0
4 Apr 22
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
4:06pm
6-K
EX-99.1
h41zf
3 Mar 22
Immunocore Reports Full Year 2021 Financial Results
7:01am
6-K
EX-99.1
i1d483s
26 Jan 22
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
4:29pm
6-K
EX-99.3
bl5wl
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
20-F
EX-2.2
s4l4z7p8
25 Mar 21
Annual report (foreign)
7:01am
20-F
EX-4.20
1fw9e
25 Mar 21
Annual report (foreign)
7:01am
20-F
jlkyne zaz9y
25 Mar 21
Annual report (foreign)
7:01am
424B4
ddxw9u7xj9g42bt
8 Feb 21
Prospectus supplement with pricing info
8:36am
F-1/A
yhov8m
3 Feb 21
Registration statement (foreign) (amended)
5:22pm
F-1/A
EX-1.1
ekybr41n6f 0z5zfmd
3 Feb 21
Registration statement (foreign) (amended)
5:22pm
F-6/A
EX-99
70y8gs6
2 Feb 21
Registration for ADRs (foreign) (amended)
4:32pm
F-1/A
tkyg vjzg
1 Feb 21
Registration statement (foreign) (amended)
6:21am
F-1/A
EX-1.1
lzueg1oo
1 Feb 21
Registration statement (foreign) (amended)
6:21am
F-1/A
EX-10.3
dsorbo44 h9p
1 Feb 21
Registration statement (foreign) (amended)
6:21am
F-1/A
EX-4.1
cmec 1mlr0sybenuy
1 Feb 21
Registration statement (foreign) (amended)
6:21am